Compare Cytokinetics Inc (CYTK) vs General Mills, Inc. (GIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs General Mills, Inc. — how do they compare? Cytokinetics Inc trades at $76.35 (market cap $10.63B), while General Mills, Inc. trades at $37.54 (market cap $20.24B). The key difference: General Mills, Inc. is the larger of the two by market cap, and General Mills, Inc. pays a 6.43% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | GIS | |
|---|---|---|
Market Cap | $10.63B | $20.24B |
Sector | Technology | Consumer Staples |
52-Week High | $87.26 | $51.11 |
52-Week Low | $34.31 | $32.17 |
Enterprise Value | $10.74B | $33.73B |
Dividend Yield | — | 6.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
General Mills (GIS) trades at $37.26, up 1.0% with a bullish technical signal. The stock shows mixed fundamentals with declining revenue ($19.49B in 2025) and negative net income margin (-0.48%), but maintains strong cash flow from operations ($2.92B). Recent earnings beat expectations in Q3 2025 and Q2 2026, while analyst sentiment remains cautious with 61% hold ratings. The company continues dividend payments and focuses on cost-saving initiatives.
Investment outlook remains balanced with attractive valuation (P/E 9.23) offset by margin pressures. Key opportunities include dividend yield and cost savings program, while risks involve declining profitability and competitive pressures. Wall Street consensus price target of $35.36 suggests limited upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →
